SCHEMBL19631552

SCHEMBL19631552

COc1ccc(CN(c2nccs2)S(=O)(=O)c2ccc(N(C)[C@H]3CCN(C(=O)OC(C)(C)C)C3)c(Cl)c2)c(OC)c1

nearest known ligand 0.40

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
SCN8A Q9UQD0 9/20 0.40
SCN1A P35498 8/20 0.40
STS P08842 2/20 0.37
EPHX2 P34913 1/20 0.37
BMP1 P13497 1/20 0.37
GPR119 Q8TDV5 4/20 0.36
CYP2C9 P11712 1/20 0.35
NR1D1 P20393 1/20 0.35
SLC2A1 P11166 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29447415 1.00 SCN8A (0.40) SCN8ASCN1ASTSEPHX2BMP1
SCHEMBL19627610 0.94 SCN8A (0.40) SCN8ASCN1ASTSEPHX2BMP1
SCHEMBL19614089 0.92 SCN8A (0.44) SCN8ASCN1ANPC1RAB9A
SCHEMBL19614091 0.92 SCN8A (0.44) SCN8ASCN1ANPC1RAB9A
SCHEMBL19631492 0.90 SCN8A (0.41) SCN8ASCN1ASTSEPHX2GPR119
SCHEMBL29447387 0.90 SCN8A (0.41) SCN8ASCN1ASTSEPHX2GPR119
SCHEMBL19634014 0.86 SCN1A (0.42) SCN8ASCN1ASTSBMP1SLC2A1
SCHEMBL19631502 0.86 SCN1A (0.42) SCN8ASCN1ASTSBMP1SLC2A1
SCHEMBL19631557 0.86 CNR1 (0.41) SCN8ASCN1ASTSBMP1SLC2A1
SCHEMBL19613480 0.86 SCN1A (0.42) SCN8ASCN1ASTSBMP1SLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200354354-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2020-11-12 US disclosed
US-10815229-B1 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2020-10-27 US disclosed
US-10662184-B2 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2020-05-26 US disclosed
US-20190194184-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2019-06-27 US disclosed
US-10246453-B2 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2019-04-02 US disclosed
WO-2017201468-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2017-11-23 WO disclosed
US-20170334902-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2017-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10815229-B1 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B SCN8A 14/4885SCN1A 1/4885STS 181/4885
US-10246453-B2 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B SCN8A 14/4885SCN1A 1/4885STS 181/4885
US-20170334902-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B SCN8A 14/4885SCN1A 1/4885STS 181/4885
US-10662184-B2 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B SCN8A 10/4885SCN1A 1/4885STS 162/4885
US-20200354354-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B SCN8A 14/4885SCN1A 1/4885STS 181/4885
US-20190194184-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B SCN8A 10/4885SCN1A 1/4885STS 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.